fluorouracil topical / Generic mfg. - LARVOL DELTA

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. (PubMed, N Engl J Med) - P3 | "Pembrolizumab led to significantly longer progression-free survival than chemotherapy when received as first-line therapy for MSI-H-dMMR metastatic colorectal cancer, with fewer treatment-related adverse events. (Funded by Merck Sharp and Dohme and by Stand Up to Cancer; KEYNOTE-177 ClinicalTrials.gov number, NCT02563002.)."

Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2029 ➔ Sep 2031 | Trial primary completion date: Sep 2029 ➔ Sep 2031

Trial completion date • Trial primary completion date • Anal Carcinoma • Colorectal Cancer • Human Immunodeficiency Virus • Infectious Disease • Oncology • Rectal Cancer • Solid Tumor • Squamous Cell Carcinoma • CD4 • IFNG

U045 Field Cancerization Therapies: Medical Dermatology and Beyond (AAD 2026) - "This session will outline the standard of care field therapies including and not limited to topical 5- fluorouracil, imiquimod, conventional/daylight photodynamic therapy, lasers, peels and other modalities. 3. Select the right candidates for field directed therapies and for a variety of cutaneous entities."

Actinic Keratosis • Dermatology • Oncology

Topical 5-fluorouracil in the treatment of vaginal intraepithelial neoplasia (vaIN): experience from the largest tertiary centre in singapore and literature review (ESGO 2026) - "Conclusion VaIN is a suitable treatment for 5-FU lesions with good regression rate. We advocate more studies evaluate the long-term outcomes of 5-FU treatment."

Review • Oncology

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - P1/2 | N=35 | Recruiting | Sponsor: Roswell Park Cancer Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. (PubMed, Lancet Oncol) - "Although the addition of cetuximab to chemotherapy improves the overall survival in some studies in patients with advanced, inoperable metastatic disease, its use in the perioperative setting in patients with operable disease confers a significant disadvantage in terms of overall survival. Cetuximab should not be used in this setting."

Clinical • Journal • P3 data • Cardiovascular • Dermatology • Gastrointestinal Cancer • Gene Therapies • Liver Cancer • Mucositis • Oncology • Pain • Stomatitis

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study (clinicaltrials.gov) - P3 | N=486 | Recruiting | Sponsor: NRG Oncology | Not yet recruiting ➔ Recruiting | Initiation date: Aug 2025 ➔ May 2026

Enrollment open • Trial initiation date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

EA2183: Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body (clinicaltrials.gov) - P3 | N=314 | Active, not recruiting | Sponsor: ECOG-ACRIN Cancer Research Group | Recruiting ➔ Active, not recruiting

Enrollment closed • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Solid Tumor • CD4 • HER-2

EAY191-A6: Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (clinicaltrials.gov) - P2 | N=66 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2026 ➔ May 2026 | Trial primary completion date: Jan 2026 ➔ May 2026

Trial completion date • Trial primary completion date • Biliary Cancer • Biliary Tract Cancer • Cholangiocarcinoma • Gallbladder Cancer • Oncology • Solid Tumor • MAPK1

Efficacy of 4% 5-Fluorouracil Cream in the Treatment of Actinic Keratoses: A Single-Center Experience. (PubMed, J Clin Med) - " Based on our analysis, 4% 5-FU cream is an effective and well-tolerated treatment for AKs, particularly in patients with extensive field cancerization. While local skin reactions are a natural part of its mechanism, they are manageable and do not outweigh clinical benefits."

Journal • Actinic Keratosis • Dermatology • Genetic Disorders • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: City of Hope Medical Center

New P1 trial • Colorectal Cancer • Oncology • Solid Tumor • CD4

Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer. (PubMed, N Engl J Med) - P3 | "Treatment included office-based ablative procedures, ablation or excision under anesthesia, or the administration of topical fluorouracil or imiquimod. Among participants with biopsy-proven anal HSIL, the risk of anal cancer was significantly lower with treatment for anal HSIL than with active monitoring. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT02135419.)."

Clinical • Journal • Anal Carcinoma • Anesthesia • Cervical Cancer • Gastrointestinal Cancer • Human Immunodeficiency Virus • Immunology • Infectious Disease • Oncology • Solid Tumor

Long-course preoperative chemoradiation vs. 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: Long-term results of the randomized Polish II study. (PubMed, Ann Oncol) - P3 | "The superiority of preoperative short-course/CCT over chemoradiation was not demonstrated."

Clinical • Journal • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Rectal Cancer • Solid Tumor

Under the midnight sun: A case of actinic keratoses in an avid Inuit fisherman. (PubMed, SAGE Open Med Case Rep) - "This case highlights the need to recognize atypical presentations of actinic keratoses in patients with darker skin phototypes and high environmental ultraviolet exposure. Topical 5% fluorouracil was initiated."

Journal • Actinic Keratosis • Dermatology • Dermatopathology

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - P1/2 | N=56 | Recruiting | Sponsor: Jonsson Comprehensive Cancer Center | Trial completion date: Mar 2026 ➔ Mar 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Trial completion date • Trial primary completion date • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer

Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - P1/2 | N=35 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute | Initiation date: Dec 2025 ➔ Mar 2026

Trial initiation date • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Topical 5-Fluorouracil Effervescent Powder in the Treatment of Vitiligo (clinicaltrials.gov) - P4 | N=60 | Recruiting | Sponsor: Al-Azhar University | Trial completion date: Oct 2024 ➔ Dec 2025 | Trial primary completion date: Oct 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Dermatology • Immunology • Vitiligo

ATOMIC: Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (clinicaltrials.gov) - P3 | N=712 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2028 ➔ Dec 2026 | Trial primary completion date: Jan 2028 ➔ Feb 2025

Mismatch repair • Trial completion date • Trial primary completion date • Tumor mutational burden • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Genetic Disorders • Oncology • Solid Tumor • CD4 • MLH1 • MSH2 • MSH6

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer (clinicaltrials.gov) - P2 | N=42 | Active, not recruiting | Sponsor: OHSU Knight Cancer Institute | N=60 ➔ 42

Enrollment change • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Mayo Clinic | Trial completion date: Jan 2026 ➔ Apr 2030 | Trial primary completion date: Jan 2026 ➔ Apr 2027

Trial completion date • Trial primary completion date • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Mazandaran University of Medical Sciences | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2025 ➔ Aug 2026 | Trial primary completion date: Oct 2025 ➔ Jul 2026

Enrollment open • Trial completion date • Trial primary completion date • Dermatology

Utilizing the VISIA Camera for Analyzing 5-Fluorouracil Treatment Efficacy for Actinic Keratosis. (PubMed, JMIR Dermatol) - "We present a case of a male patient diagnosed with diffuse scalp actinic keratoses who was treated with topical 5-fluorouracil (5-FU). Results revealed a decrease in UV spots, a temporary improvement in texture followed by a later rise, and no significant change in generalized spots. This case highlights the value of VISIA imaging as an objective method for assessing treatment response and evaluating the effectiveness of 5-FU in the management of actinic keratoses."

Journal • Actinic Keratosis • Dermatology

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial (clinicaltrials.gov) - P3 | N=129 | Not yet recruiting | Sponsor: City of Hope Medical Center

New P3 trial • Appendix Cancer • Colorectal Cancer • Oncology • Solid Tumor

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - P2 | N=128 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Dec 2025 ➔ Dec 2027 | Trial primary completion date: Dec 2025 ➔ Dec 2027

Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Mar 2026 ➔ Mar 2029 | Trial primary completion date: Mar 2026 ➔ Mar 2029

Trial completion date • Trial primary completion date • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • PD-L1